- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
1 Online-Ressource.
- Sprache
-
Englisch
- Erschienen in
-
PARP Inhibitors in Breast Cancer: a Short Communication ; volume:26 ; number:2 ; day:2 ; month:1 ; year:2024 ; pages:103-113 ; date:2.2024
Current oncology reports ; 26, Heft 2 (2.1.2024), 103-113, 2.2024
- Urheber
-
Daly, Gordon R.
AlRawashdeh, Maen Monketh
McGrath, Jason
Dowling, Gavin P.
Cox, Luke
Naidoo, Sindhuja
Vareslija, Damir
Hill, Arnold D. K.
Young, Leonie
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1007/s11912-023-01488-0
- URN
-
urn:nbn:de:101:1-2404301316474.583297901802
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 11:01 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Daly, Gordon R.
- AlRawashdeh, Maen Monketh
- McGrath, Jason
- Dowling, Gavin P.
- Cox, Luke
- Naidoo, Sindhuja
- Vareslija, Damir
- Hill, Arnold D. K.
- Young, Leonie
- SpringerLink (Online service)
Ähnliche Objekte (12)
PARP inhibitors
An Overview of PARP Inhibitors for the Treatment of Breast Cancer
53BP1 depletion causes PARP inhibitor resistance in ATM-deficient breast cancer cells
Advances and perspectives of PARP inhibitors
Rad51 inhibition sensitizes breast cancer stem cells to PARP inhibitor in triple-negative breast cancer
PARP inhibitors in the management of breast cancer: current data and future prospects
PARP Inhibitors in Ovarian Cancer: A Review
Erratum to: 53BP1 depletion causes PARP inhibitor resistance in ATM-deficient breast cancer cells
PARP inhibitors in the treatment of ovarian cancer
Transcription–replication conflicts underlie sensitivity to PARP inhibitors
Prostate cancer and PARP inhibitors: progress and challenges
Pharmacokinetics and Pharmacodynamics of PARP Inhibitors in Oncology
PARP inhibitors
An Overview of PARP Inhibitors for the Treatment of Breast Cancer
53BP1 depletion causes PARP inhibitor resistance in ATM-deficient breast cancer cells
Advances and perspectives of PARP inhibitors
Rad51 inhibition sensitizes breast cancer stem cells to PARP inhibitor in triple-negative breast cancer
PARP inhibitors in the management of breast cancer: current data and future prospects
PARP Inhibitors in Ovarian Cancer: A Review
Erratum to: 53BP1 depletion causes PARP inhibitor resistance in ATM-deficient breast cancer cells
PARP inhibitors in the treatment of ovarian cancer
Transcription–replication conflicts underlie sensitivity to PARP inhibitors
Prostate cancer and PARP inhibitors: progress and challenges
Pharmacokinetics and Pharmacodynamics of PARP Inhibitors in Oncology
PARP inhibitors
An Overview of PARP Inhibitors for the Treatment of Breast Cancer
53BP1 depletion causes PARP inhibitor resistance in ATM-deficient breast cancer cells
Advances and perspectives of PARP inhibitors
Rad51 inhibition sensitizes breast cancer stem cells to PARP inhibitor in triple-negative breast cancer
PARP inhibitors in the management of breast cancer: current data and future prospects
PARP Inhibitors in Ovarian Cancer: A Review
Erratum to: 53BP1 depletion causes PARP inhibitor resistance in ATM-deficient breast cancer cells
PARP inhibitors in the treatment of ovarian cancer
Transcription–replication conflicts underlie sensitivity to PARP inhibitors
Prostate cancer and PARP inhibitors: progress and challenges